Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutra Pharma has announced that its wholly-owned drug discovery subsidiary, ReceptoPharm, has reported initial positive safety data from its Phase IIb/IIIa clinical study of RPI-78M for treating adrenomyeloneuropathy.
Subscribe to our email newsletter
Paul Reid, CEO of ReceptoPharm, said: “Initial reports and feedback from physicians involved with this clinical study have reported that patients have experienced no adverse side effects from RPI-78M.
“This is an important indicator of the success of this clinical study, as it provides the medical and pharmacological communities with early evidence supporting the safety of our leading drug candidate, RPI-78M.”
The company has applied for orphan drug status in the US and intends on doing so for the EU. ReceptoPharm expects to present the complete clinical findings and data from this study by the end of September 2008.
RPI-78M is ReceptoPharm’s leading drug candidate for treating neurological and autoimmune disorders.